Categories: BabyTechDeliveryLifePlatformTechnology
Life Changing, Re-Dosable Gene Therapies: we are committed to longer, healthier lives for all, including kids and adults who can’t currently be treated. With EVADER™, our next generation, AAV based gene therapy platform technology we are addressing the limitations of current alternatives.
Investors 5
Mentions in press and media 2
| Date | Title | Description |
| 19.07.2022 | Chameleon Biosciences Founder to Speak at Next Generation Gene Therapy Vectors Summit 2022 in Boston | Immunology and gene therapy CEO and scientist presents innovative vector modifications at industry summit BERKELEY, CA, USA, July 19, 2022 /EINPresswire.com/ -- Chameleon Biosciences Inc., a biotechnology company focused on an innovative ap... |
| 29.04.2022 | Chameleon Biosciences, Inc. Founder CEO, Genine Winslow on how they are Expanding AAV Gene Therapies with EVADER™ | Genine Winslow, Founder CEO, Chameleon Biosciences, Inc.
CEOCFO I Interviews Chameleon Biosciences, Inc. Co-CEO Genine Winslow, discusses their Adeno Associated Virus Gene Therapy
We are addressing a need, a gaping hole in the gene therapy ... |
Reviews 0
